The UK isn’t rejecting medicines. It’s losing them before NICE even sees them.

That’s the evolving reality of 2026. And it’s a fundamental shift obscured by a kind of geopolitical purdah, as competing interests and strategic caution leave everyone unwilling to confront it directly.

In my MFN piece, “MFN is quietly reshaping how you launch globally”, I argued that policy and payer signals are now shaping launch sequencing in very tangible ways. The UK is a case study in what happens when “the model” changes faster than the system that assumes it will behave predictably.

Traditionally, everyone focuses on NICE:

  • Delays

  • Threshold changes

  • Backlogs

But if you track what’s happening across technology appraisals, a different pattern emerges, one that should worry anyone who cares about access.

A growing number of appraisals in 2026 aren’t being rejected. They’re being stopped.

Not because the evidence failed or because the ICER was too high, but because the company didn’t submit.

This should make us pause. It should be causing alarm within the government. What must be true for a company to decide the UK isn’t even worth engaging with?

Then you notice the second shift: “not recommended” decisions are becoming less visible—not because medicines are suddenly more cost-effective, but because NICE is holding decisions in limbo.

Too expensive at £20–30k.

Potentially acceptable at £25–35k.

So instead of a decision, we get delay.

And this is where the headline risk of 2026 gets misunderstood. Fewer rejections isn’t stability. It’s deferral.

We’re seeing a structural change in behaviour:

  • Companies withdraw instead of fail

  • NICE pauses instead of rejects

  • Decisions disappear from the pipeline entirely

The consequence is an access loss that doesn’t show up cleanly in the data.

A drug that gets a “no” is visible.

A drug in the Cancer Drugs Fund is visible.

But a drug that is never submitted, quietly paused, sequenced out of the UK, simply disappears.

That’s the gap. It’s growing. And it’s being driven by the same logic I’ve outlined with MFN: the commercial equation is breaking earlier in the pathway, and launch sequencing is being recalibrated in real time.

Pharma behaviour is adapting quickly:

  • The UK moves later in launch sequencing

  • Commercial thresholds are applied earlier

  • More assets are filtered out before NICE engagement begins

This is not because companies don’t want UK access. But because the pathway has become a higher-risk, lower-value step sooner than it used to.

Which leaves us here:

A system designed to protect value.

A market responding by protecting price.

And patients caught in a widening timing gap between the two.

This is not a rejection problem. It’s a disengagement problem. And that has a very practical implication: when the national route stalls, the pressure doesn’t disappear. It moves.

Into ICBs.

Into Cancer Alliances.

Into local pathways and initiation decisions.

That’s where the next phase plays out—not in the appraisal, but after it.

The uncomfortable question is this: if more medicines never reach NICE, what does access look like in two years?

I’m interested in what others are seeing:

·       Are more assets being held back pre-submission?

·       Are UK timelines slipping in your therapy areas?

·       Are global teams rethinking where the UK sits in launch sequencing?

It feels like a tipping point. We just haven’t labelled it yet.